Prognostic impact of left ventricular mass change in patients with ST-elevation myocardial infarction

Area of Science:

• Cardiology
• Clinical Outcomes Research
• Echocardiography

Background:

• The prognostic significance of left ventricular hypertrophy (LVH) progression in ST-elevation myocardial infarction (STEMI) patients is not well-established.
• Understanding the impact of LVH changes on clinical outcomes is vital for risk stratification.

Purpose of the Study:

• To investigate the prognostic impact of left ventricular mass index (LVMI) progression on clinical outcomes in patients with STEMI.
• To determine if increased LVMI predicts adverse cardiac events post-STEMI.

Main Methods:

• Analysis of clinical outcomes and echocardiographic data from 200 STEMI patients with successful coronary intervention and 12-36 month follow-up.
• Patients were categorized into progression and non-progression groups based on a >10% increase in LVMI.
• Major adverse cardiac events (MACE) within 5 years were tracked, including death, recurrent MI, TVR, and heart failure hospitalization.

Main Results:

• LVMI progression was observed in 55 patients (27.5%).
• The progression group exhibited a significantly higher rate of recurrent myocardial infarction (MI) (13% vs. 2%, P=.026) and worse event-free survival for recurrent MI (log-rank P<.001).
• Progression of LVMI was an independent predictor of recurrent MI (Adjusted Hazard Ratio: 10.253, P=.005).

Conclusions:

• Increased LVMI is an independent predictor of adverse events, particularly recurrent MI, in STEMI patients.
• Progression of LVH following STEMI warrants close monitoring due to its association with poor clinical outcomes.
• Echocardiographic assessment of LVMI changes can aid in risk stratification for STEMI survivors.